Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.39 |
| ▸ | HCN1 | O60741 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2325440 | 0.83 | NPC1 (0.50) | KCNK3KCNK9ALDH1A1 | |
| SCHEMBL2329563 | 0.80 | KCNK3 (0.49) | F2RKCNK3KCNK9HCRTR1HCRTR2 | |
| SCHEMBL2327750 | 0.79 | NPC1 (0.45) | ALDH1A1 | |
| SCHEMBL13780116 | 0.78 | F2R (0.50) | F2RKCNK3KCNK9HCRTR1HCRTR2 | |
| SCHEMBL1549244 | 0.77 | KMT2A (0.48) | ALDH1A1 | |
| SCHEMBL27775785 | 0.77 | KCNK3 (0.46) | F2RKCNK3KCNK9HCRTR1HCRTR2 | |
| SCHEMBL2322233 | 0.76 | ERCC5 (0.44) | ALDH1A1 | |
| SCHEMBL2325182 | 0.75 | SLC6A2 (0.39) | KCNK3KCNK9ALDH1A1 | |
| SCHEMBL1127848 | 0.73 | TSHR (0.62) | F2RKCNK3KCNK9HCRTR1HCRTR2 | |
| SCHEMBL1550118 | 0.73 | EPHX2 (0.39) | KCNK3KCNK9HCRTR1HCRTR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1904455-B1 | PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-7678795-B2 | Pyridazines as 11b-HSD1 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| EP-1904455-A2 | PYRIDAZINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HOFFMANN-LA ROCHE INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007003521-A2 | PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010519-A1 | New pyridazines as 11B-HSD1 inhibitors | HSD11B1, HSD17B1, HSD17B11 | F2R 672/4885KCNK3 2881/4885KCNK9 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.